1. Market Research
  2. > Business Services
  3. > Education and Training Market Trends
  4. > Effective sales and marketing strategies for drugs with companion diagnostics

Effective sales and marketing strategies for drugs with companion diagnostics

  • May 2013
  • -
  • Firstword Pharma
  • -
  • 69 pages

Summary

Table of Contents





To fully exploit the commercial advantages of companion diagnostics, Pharma companies need to rethink fundamentally their drug development and marketing strategies.

Everyone is a winner with companion diagnostics. The ability to accurately diagnose specific patient subsets is allowing drugs to be targeted only at those patients who will respond to treatment. Patients benefit from effective treatment and reduced side effects. Payers benefit from drugs that are now only used in patients for whom they are effective whilst the pharma industry, cautious about the potential impact of lower prescribing volumes, can benefit in the long term from effectively positioning its product.

Despite these advantages there remain a number of challenges for the sector. Regulation has failed to keep up with the speed of market development, differing cultural preferences - sharply contrasted in the US and Europe - are affecting take up, not all stakeholders are sufficiently informed and onboard while the uncertain reimbursement status in some markets is frustrating the sector’s development. What can Pharma and Diagnostic companies do to effect change?





Key Benefits

Through detailed case studies and expert industry input this invaluable report identifies the essential ingredients needed to successfully market a biologic drug and its companion diagnostic. Old models of selling and branding need to be adapted to the new market realities and partnership working with wider stakeholder education and integrated sales training all have a part to play. Learn from the experience and insights of front line experts from industry leading companies such as Pfizer, Boehringer Ingelheim, Qiagen and Diaceutics.






Key Questions Answered


How can you work with laboratories to ensure that companion diagnostics are seen positively and not competitively?
What role can patient advocacy groups play?
At what development stage should Pharma and Diagnostics teams be working together?
To what degree should the value proposition of the brand be related to the role of the accompanying diagnostic?
What alternatives are there to company funding of testing in markets where diagnostic reimbursement is not available?


This report will help you to:


Appreciate the complex and evolving regulatory environment which is shaping the market
Understand why clinical laboratories are critical in ensuring wide adoption
Incorporate joint working at an early stage to ensure harmonised approval with integrated marketing messages and programmes
Develop education programmes which will support patient confidence and clinician support
Introduce support and marketing structures which encourage diagnostic testing






Expert Views Include:


Dr Austin Finley, consultant, RxDxExperts (US)
Susan Holz, associate director of public relations, Boehringer Ingelheim (US)
Peter Keeling, chief executive office, Diaceutics (Northern Ireland)
Kevin Lokay, vice-president and business unit head, oncology, Boehringer Ingelheim (US)
Andy Schmeltz, US region president, oncology business unit, Pfizer
Dr Thomas Theuringer, director public relations, Qiagen (Germany)
Dr Carole Welsch, associate director, regional marketing of personalised healthcare, North America, Qiagen


Key Quotes

“This is a multidisciplinary approach. This is really a joint effort between global colleagues who want to ensure that there is a global strategy being implemented from the launch perspective, so the same drug and same test are being launched across the globe.” – Dr Carole Welsch, associate director, regional marketing of personalised healthcare at Qiagen North America

“The group sitting beside the physician and therefore often helping the physician take the decision around what the test result was is the laboratorian and pathologist - not the diagnostic company, not the payer, not the regulator, but the lab. The labs are the ones that are in the frontline.” – Peter Keeling, chief executive officer, Diaceutics

“The whole concept of personalised medicine is that you’re selecting in the clinical trial this patient population, so there needs to be a diagnostic technology and platform that’s used in those pivotal Phase III trials, the registration trials, that’s going to be part of your label. Therefore thinking about this is definitely something that has to come early in your clinical development programme when you think about the Dx technology platform that’s going to be most appropriate not only for the clinical trial programme to select the patients but also to ensure that that technology or technical platform is going to be widely available so that it’s not going to be a barrier to patients once the drug’s approved.” – Andy Schmeltz, US region president, oncology business unit, Pfizer


Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
Get This Report
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Cognitive Assessment and Training Market by Assessment Type (Pen- and Paper-Based, Hosted, Biometrics), Component, Application (Clinical Trial, Screening & Diagnostics, Brain Training, Academic Research), Vertical, and Region - Global Forecast to 2021

Cognitive Assessment and Training Market by Assessment Type (Pen- and Paper-Based, Hosted, Biometrics), Component, Application (Clinical Trial, Screening & Diagnostics, Brain Training, Academic Research), Vertical, and Region - Global Forecast to 2021

  • $ 7150
  • Industry report
  • April 2017
  • by MarketsandMarkets

Rapidly aging global population, increasing awareness about brain fitness, and advancements in technology are driving the cognitive assessment and training market The cognitive assessment and training ...

Consumer IAM Market by Solution (Directory, Identity Proofing, Identity Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region - Global Forecast to 2022

Consumer IAM Market by Solution (Directory, Identity Proofing, Identity Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region - Global Forecast to 2022

  • $ 5650
  • Industry report
  • April 2017
  • by MarketsandMarkets

“The growing concern for consumer identity management will drive the consumer IAM market” The consumer Identity and Access Management (IAM) market is expected to grow from USD 14.30 billion in 2017 ...

Massive Open Online Courses (MOOC) Market: By Provider Type (University, Private Company, Government) Course Length (1-4 weeks, 4-8 weeks, Others) Language (English, French, Japanese, French, German, Others) Pricing Options (Free, Paid) -Forecast (2017-20

Massive Open Online Courses (MOOC) Market: By Provider Type (University, Private Company, Government) Course Length (1-4 weeks, 4-8 weeks, Others) Language (English, French, Japanese, French, German, Others) Pricing Options (Free, Paid) -Forecast (2017-20

  • $ 5250
  • Industry report
  • January 2017
  • by Industry ARC

MOOC or Massive Open Online Courses are online educational courses which can be accessed by unlimited number of students. These are provided by private companies, non-profit organizations, government institutions ...


ref:plp2013

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.